CGT4859

Phase 2

Cogent Biosciences, Inc. (COGT)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Mar '27

COGTPhase 2$5.9B

CGT4859 Phase 2 Est. Readout

CGT4859• Intrahepatic Cholangiocarcinoma (Icc)110

Mar 2027~Confirmed

CT.gov

00%

Competitive Landscape

0 competitors in Intrahepatic Cholangiocarcinoma (Icc)

View Full Landscape

Drug Information

Target Indication

Intrahepatic Cholangiocarcinoma (Icc)

Clinical Trial

NCT06777316

Last updated: 12/4/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

COGT

Cogent Biosciences, Inc.

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

CGT9486 plus sunitinibPhase 3

Advanced Gastrointestinal Stromal Tumors

CGT9486Phase 3

Gastrointestinal Stromal Tumors

bezuclastinibPhase 2

Advanced Systemic Mastocytosis (AdvSM)

Bezuclastinib Tablets (Formulation A)Phase 2

SSM

Bezuclastinib in combination with sunitinibPhase 2

Gastrointestinal Stromal Tumors

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts